IP Library Granted Patent US 9,700,572
Granted Patent B2
US 9,700,572 · App. 14/494,637 · Granted Jul 11, 2017

Anti-cancer agent

Inventors: Hiroyasu Esumi (Kashiwa, JP); Masafumi Ikeda (Kashiwa, JP); Chika Miyoshi (Kashiwa, JP); Shigetoshi Kadota (Toyama, JP); Toshiki Okubo (Takaoka, JP); Satoshi Yomoda (Takaoka, JP); Takafumi Fuse (Takaoka, JP); Takanori Kawashima (Takaoka, JP); Shigeki Chiba (Takaoka, JP)
Assignees: National Cancer Center; Kracie Pharma, Ltd.; National University Corporation University of Toyama
A61K31/7048A61K31/341A61K31/365A61K31/7034A61K36/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,700,572
App. No.
14/494,637
Granted
Jul 11, 2017
Kind
B2
Abstract

The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.

Claims (6)

1. A method of treating pancreatic cancer comprising administering to a human patient in need thereof, a dose of arctigenin of at least 148.5 mg per day.

2. The method of claim 1 , further comprising administering to said patient a dose of arctiin of at least 171.25 mg per day.

3. The method of claim 1 or claim 2 , wherein said pancreatic cancer is refractory to treatment with gemcitabine.

4. The method of claim 2 , wherein said method of treating pancreatic cancer comprises reducing recurrences and metastases of pancreatic cancer which occur after cancer treatment.

5. A method of inhibiting pancreatic cancer stem cells comprising administering to said human patient in need thereof, a composition comprising arctigenin at a dose of at least 148.5 mg or more per day.

6. A method for reducing recurrences and metastases of pancreatic cancer which occur after cancer treatment in a human patient, comprising administering a composition containing arctigenin in a dose of at least 148.5 mg per day to said patient.

Assignments (5)
MERGER Recorded Jun 20, 2024
From: KRACIE PHARMA, LTD.
To: KRACIE HOLDINGS, LTD.
Reel/Frame 067794/0001 →
CHANGE OF NAME Recorded Jun 20, 2024
From: KRACIE HOLDINGS, LTD.
To: KRACIE, LTD.
Reel/Frame 067794/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2014
From: ESUMI, HIROYASU; IKEDA, MASAFUMI; MIYOSHI, CHIKA
To: NATIONAL CANCER CENTER
Reel/Frame 034349/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2014
From: KADOTA, SHIGETOSHI
To: NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA
Reel/Frame 034350/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2014
From: OKUBO, TOSHIKI; YOMODA, SATOSHI; FUSE, TAKAFUMI; KAWASHIMA, TAKANORI; CHIBA, SHIGEKI
To: KRACIE PHARMA, LTD.
Reel/Frame 034350/0724 →
Priority Claims (1)
JP 2012-069964 · Mar 26, 2012 · national
Continuity (2)
Continuation PCTJP2013058692 · Mar 26, 2013
Related Publication 20150196576A1 · Jul 16, 2015